



VIA HAND DELIVERY SEPTEMBER 5, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Application of: Meissner et al.

SEP 10 2001

Application Number: 09/393,023

Group Art Unit: 1646

TECH CENTER 1600/2900

Filed: September 9, 1999

Examiner: Kaufman, C.

Title: Human Criptin Growth Factor

Attny. Docket No.: PF200D1

#16
HQJ
9/11/01

**RESPONSE TO FURTHER RESTRICTION REQUIREMENT, PROVISIONAL
ELECTION, AND TRAVERSE UNDER 37 C.F.R. § 1.143**

Commissioner for Patents and Trademarks
Washington, D.C. 20231

Sir or Madam:

In response to the Further Restriction Requirement mailed July 6, 2001, please enter the following provisional election, with traverse, and consider the remarks below. Applicants submit concurrently herewith: (a) a Petition for an Extension of Time for one (1) month, up to and including September 6, 2001; (b) a Fee Transmittal Sheet; and (c) Associate Power of Attorney.

Remarks

Claims 14, 16, and 19-95 are pending in the instant application.

Applicants request reconsideration and withdrawal of the present restriction requirement.

The Restriction Requirement

The Examiner appears to be requiring an election of "species" (i.e., sequence) within the provisionally elected Group I.

More particularly, the Examiner alleges:

The claims are drawn to numerous patentably distinct proteins, each of which constitutes a patentably distinct product. Applicants are required to elect a single invention of a protein, selected from the group consisting of: a protein comprising a polypeptide selected from the group consisting of the following regions of SEQ ID NO:2: Residues 1-223, 1-173, 24-223, 24-67, 24-173, 45-128, 68-173, 68-223, 129-207 and 174-223 (including polypeptides \geq 90% identical; i.e., elect one from the previous Markush group), and a single ultimate species of a fragment of residues 1-223 which retains